Filtered By:
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 2502 results found since Jan 2013.
Case of incidental thoracic spinal dumbbell hemorrhagic arachnoid cyst and tentorial metastasis from breast carcinoma
CONCLUSION: A 50-year-old female underwent a left retrosigmoid suboccipital craniectomy for removal of a tentorial metastasis from breast carcinoma, followed by radiation/chemotherapy. Three months later, she hemorrhaged into an MR-documented T10-T11 dumbell extradural SAC that was successfully treated with laminectomy, marsupialization, and excision.PMID:36895243 | PMC:PMC9990811 | DOI:10.25259/SNI_66_2023
Source: Surgical Neurology International - March 10, 2023 Category: Neurosurgery Authors: Gianluca Scalia Roberta Costanzo Manikon Poullay Silven Domenico Gerardo Iacopino Giovanni Federico Nicoletti Gianluca Galvano Giuseppe Emmanuele Umana Source Type: research
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial
ConclusionThis interim analysis supports feasibility and acceptability of a novel VR intervention to target psychological symptoms for PBT patients. Trial enrollment will continue to assess for intervention efficacy.Trial RegistrationNCT04301089 registered on 3/9/2020.
Source: Journal of Neuro-Oncology - March 8, 2023 Category: Cancer & Oncology Source Type: research
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Neuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical
SetPoint Medical, a medtech company based in California, is developing a neuromodulatory device that is intended to treat rheumatoid arthritis. The overlap between the nervous and immune systems is increasingly appreciated, and this technology aims t...
Source: Medgadget - February 28, 2023 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Medicine Neurology autoimmune immunology SetPointMed Source Type: blogs
Late diagnosis of tuberous sclerosis complex in a 40-year-old female presenting with abdominal pain: a case report
Ann Med Surg (Lond). 2023 Feb 7;85(2):203-207. doi: 10.1097/MS9.0000000000000149. eCollection 2023 Feb.ABSTRACTTuberous sclerosis (TS) is a rare autosomal-dominant neurocutaneous disorder that is characterized by hamartomas affecting a variety of organs, including the brain, heart, kidneys, skin, lungs, and liver. TS can emerge in a wide variety of clinical and phenotypic forms at any age, all with varying degrees of severity, and is brought on by mutations in the tumor suppressor genes TSC1 or TSC2. This case report is about a 40-year-old female with facial angiofibromas and abdominal symptoms who was referred to the radi...
Source: Annals of Medicine - February 27, 2023 Category: Internal Medicine Authors: Sajiva Aryal Suraj Sharma Saman Aryal Vikash Bhattarai Source Type: research
Mixed Primary Hepatocellular Carcinoma and Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review
Medicina (Kaunas). 2023 Feb 20;59(2):418. doi: 10.3390/medicina59020418.ABSTRACTMixed hepatocellular carcinoma with neuroendocrine carcinoma (HCC-NEC) is extremely rare, comprising about 0.46% of primary hepatic tumors. A 63-year-old man who was a chronic alcoholic presented with a nine-centimeter-sized hepatic mass. His serum alpha-fetoprotein and protein induced by vitamin K antagonist-II levels were 22,815 ng/mL and 183 mAU/mL, respectively. The patient underwent a right hemihepatectomy, including the middle hepatic vein. The tumor consisted of poorly differentiated HCC (20%) and large- and small-cell-type NEC (80%) com...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Woo Young Shin Keon Young Lee Kyeong Deok Kim Source Type: research
